lymphoblastic leukaemia (ALL)

The US Food and Drug Administration (FDA) has approved a targeted therapy, Besponsa (inotuzumab ozogamicin), for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). Read more


MyTomorrows and Spectrum Pharmaceuticals team up to provide access to liposome-encapsulated vincristine for the treatment of Philadelphia chromosome negative acute lymphoblastic leukaemia Read more


CTL019, is the first personalised cellular therapy for the treatment of cancer to receive this important classification. Read more

UK pharmaceutical firm Nova Laboratories has secured FDA approval for its acute lymphoblastic leukaemia (ALL) product Xaluprine, following a NDA to the organisation in July 2013. The drug, which will be marketed in the US as Purixan, is a 20 mg/ml... Read more